Skip to main content

Table 2 Clinicopathologic characteristics and immunohistochemical expression of biomarkers

From: Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases

Features

Groups

(n)

gH2AX, %

median

(range)

n = 75

P

RPA2, %

median

(range)

n = 74

P

sTIL, %

median

(range)

n = 76

P

iTIL, %

median

(range)

n = 76

P

tcPD-L1,%

median

(range)

n = 73

P

icPD-L1, %

median (range)

n = 73

P

Age at diagnosisa,c

 ≤ 50 (5)

 > 50 (71)

63 (30–85)

42 (5–85)

0.711

44 (20–73)

44 (3–81)

0.800

12 (5–30)

5 (0–60)

0.061

0 (0–5)

0 (0–20)

0.052

23 (0–100)

3 (0–100)

0.525

40 (5–60)

5 (0–80)

0.461

Gradea

1 (2)

2 (10)

3 (64)

70 (70–70)

42 (6–85)

43 (5–85)

0.860

20 (20–20)

52 (3–75)

44 (3–81)

0.985

5 (5–5)

2 (0–40)

5 (0–60)

0.404

0 (0–0)

1 (0–20)

0 (0–20)

0.907

0 (0–0)

1 (0–40)

5 (0–100)

0.138

16 (1–30)

0 (0–80)

20 (0–70)

0.248

Pathological tumor size (mm)a,c

 ≤ 20 (20)

21–50 (38)

 > 50 (17)

60 (8–85)

36 (6–85)

40 (5–79)

0.154

45 (0–60)

44 (3–81)

32 (4–80)

0.385

5 (0–60)

4 (0–40)

2 (0–50)

0.093

0 (0–20)

1 (0–20)

1 (0–5)

0.074

0 (0–80)

7 (0–100)

10 (0–80)

0.033

3 (0–60)

18 (0–80)

10 (0–60)

0.937

Pathological nodal stagea

N0 (57)

N1 (7)

N2 (2)

N3 (3)

43 (6–85)

32 (5–83)

49 (19–79)

27 (11–28)

0.255

40 (3–80)

45 (4–65)

53 (25–80)

44 (38–75)

0.529

5 (0–50)

5 (0–50)

10 (0–20)

10 (7–25)

0.284

0 (0–20)

0 (0–2)

0 (0–0)

0 (0–2)

0.162

5 (0–100)

7 (0–80)

8 (6–10)

3 (0–15)

0.717

20 (0–80)

10 (0–60)

35 (0–70)

1 (0–15)

0.644

ER b

 > 10% (9)

 < 10% (67)

47 (8–80)

43 (5–85)

1.000

50 (7–81)

44 (3–80)

0.399

5 (0–40)

5 (0–60)

0.452

1 (0–20)

0 (0–20)

0.673

10 (0–80)

3 (0–100)

0.240

20 (0–80)

5 (0–70)

0.420

PRb

 > 10% (2)

 < 10% (74)

42 (8–75)

43 (5–85)

0.833

45 (20–70)

44 (3–81)

0.831

4 (2–5)

5 (0–60)

0.909

0 (0–0)

0 (0–20)

0.295

0 (0–0)

3 (0–100)

0.171

30 (0–60)

10 (0–80)

0.804

HER2b

Positive (3)

Negative (73)

67 (11–73)

43 (5–85)

0.889

69 (44–70)

43 (3–81)

0.199

50 (25–60)

5 (0–50)

0.001

2 (1–2)

0 (0–20)

0.222

1 (0–15)

3 (0–100)

0.743

1 (0–30)

10 (0–80)

0.743

Ki-67b

 < 20% (9)

 ≥ 20% (67)

37 (6–85)

44 (5–85)

0.696

30 (3–75)

44 (3–81)

0.836

3 (0–40)

5 (0–60)

0.565

0 (0–20)

0 (0–20)

0.604

10 (0–100)

3 (0–100)

0.560

4 (0–80)

10 (0–70)

0.972

Basal phenotypeb

Yes (13)

No (61)

44 (5–85)

40 (8–83)

0.925

46 (3–81)

38 (3–80)

0.739

5 (0–60)

5 (0–30)

0.563

1 (0–20)

0 (0–20)

0.048

3 (0–100)

3 (0–80)

0.794

13 (0–80)

1 (0–60)

0.917

  1. sTIL stromal tumor-infiltrating lymphocytes, iTIL intratumoral tumor-infiltrating lymphocytes, tcPD-L1 tumor cell-PD-L1, icPD-L1 immune cell PD-L1, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2
  2. aSpearmann rank correlation coefficient
  3. bMann-Whitney
  4. cTested as Spearmann rank correlation coefficient with age and tumor size as continuous variables
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us